MXPA04010544A - Tratamiento del sindrome metabolico. - Google Patents

Tratamiento del sindrome metabolico.

Info

Publication number
MXPA04010544A
MXPA04010544A MXPA04010544A MXPA04010544A MXPA04010544A MX PA04010544 A MXPA04010544 A MX PA04010544A MX PA04010544 A MXPA04010544 A MX PA04010544A MX PA04010544 A MXPA04010544 A MX PA04010544A MX PA04010544 A MXPA04010544 A MX PA04010544A
Authority
MX
Mexico
Prior art keywords
growth hormone
insulin
treatment
patients
sensitizing agent
Prior art date
Application number
MXPA04010544A
Other languages
English (en)
Spanish (es)
Inventor
Saller Bernhard
Original Assignee
Pfizer Health Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0209642A external-priority patent/GB0209642D0/en
Priority claimed from GB0218912A external-priority patent/GB0218912D0/en
Application filed by Pfizer Health Ab filed Critical Pfizer Health Ab
Publication of MXPA04010544A publication Critical patent/MXPA04010544A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
MXPA04010544A 2002-04-26 2003-04-24 Tratamiento del sindrome metabolico. MXPA04010544A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0209642A GB0209642D0 (en) 2002-04-26 2002-04-26 Metabolic syndrome
GB0218912A GB0218912D0 (en) 2002-08-14 2002-08-14 Metabolic syndrome
PCT/EP2003/004357 WO2003090784A1 (en) 2002-04-26 2003-04-24 Treatment of metabolic syndrome

Publications (1)

Publication Number Publication Date
MXPA04010544A true MXPA04010544A (es) 2005-08-16

Family

ID=29272006

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04010544A MXPA04010544A (es) 2002-04-26 2003-04-24 Tratamiento del sindrome metabolico.

Country Status (11)

Country Link
EP (1) EP1499357A1 (pt)
JP (1) JP2005523915A (pt)
KR (1) KR20040101545A (pt)
CN (1) CN1646167A (pt)
AU (1) AU2003227683A1 (pt)
BR (1) BR0309375A (pt)
CA (1) CA2483005A1 (pt)
IL (1) IL164670A0 (pt)
MX (1) MXPA04010544A (pt)
PL (1) PL372900A1 (pt)
WO (1) WO2003090784A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10231976B2 (en) * 2010-02-08 2019-03-19 Prairie Pharmaceuticals LLC Methods for the use of progestogen as a glucocorticoid sensitizer

Also Published As

Publication number Publication date
JP2005523915A (ja) 2005-08-11
PL372900A1 (en) 2005-08-08
KR20040101545A (ko) 2004-12-02
BR0309375A (pt) 2005-03-29
AU2003227683A1 (en) 2003-11-10
CA2483005A1 (en) 2003-11-06
WO2003090784A1 (en) 2003-11-06
CN1646167A (zh) 2005-07-27
EP1499357A1 (en) 2005-01-26
IL164670A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
EP0984780B1 (en) Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome and gestational diabetes
KR101847485B1 (ko) 초속효성 인슐린의 용도
US5457109A (en) Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
RU2440143C2 (ru) Применение ингибитора dpp-iv для снижения приступов гликемии
JP3821839B2 (ja) 胃腸の運動性を調節する方法
Willi et al. Troglitazone antagonizes metabolic effects of glucocorticoids in humans: effects on glucose tolerance, insulin sensitivity, suppression of free fatty acids, and leptin
KR20000071179A (ko) 당뇨병 치료용 술포닐우레아-글리타존 상승효과 배합물
Kokot et al. Plasma leptin concentration in kidney transplant patients during the early post-transplant period.
Lucas-Morante et al. Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201–995 before transsphenoidal surgery
Vilsbøll et al. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
JP2009539803A (ja) ソマトスタチン−アナログとドーパミン−または成長ホルモン受容体アンタゴニストの組合せ剤
Herrmann et al. Effects of a combination of recombinant human growth hormone with metformin on glucose metabolism and body composition in patients with metabolic syndrome
CN104321074B (zh) 生长抑素类似物与11β‑羟化酶抑制剂的组合
US5874454A (en) Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
MXPA04010544A (es) Tratamiento del sindrome metabolico.
EP1874355A2 (en) Method of treatment using gh antagonist and somatostatin agonist
Saito et al. Plasma somatostatin in normal subjects and in various diseases: increased levels in somatostatin-producing tumors
US6046202A (en) Use of thiazolidinedione derivatives in the treatment of insulin resistance
ZA200408437B (en) Treatment of metabolic syndrome
Kutoh et al. Efficacy and safety of dulaglutide in patients with absolute insulin deficiency
US11666634B2 (en) Methods and compositions for management of gastrointestinal disorders
LAMBADIARI et al. Metreleptin as A Rescue Therapy in A Patient With A Novel Mutation for Familial Partial Lipodystrophy Type 3, Originally Presenting as Type 1 Diabetes.
Okamoto et al. Efficacy and Safety of Semaglutide in Glycemic Control and Body Weight Management Among Obese Type 2 Diabetes Patients Initiated or Switched to Semaglutide From Other GLP-1 Receptor Agonists
VINIK et al. Familial hyperinsulinemia associated with secretion of an abnormal insulin, and coexistence of insulin resistance in the propositus
Olczak et al. Post-receptor insulin resistance after diazoxide in non-insulin dependent diabetes

Legal Events

Date Code Title Description
FG Grant or registration